September 9, 2014 — Accuray Inc. announced it has been awarded a new exclusive three-year group purchasing agreement with Premier Inc., covering the CyberKnife M6 and TomoTherapy HDA product portfolios. The Accuray and Premier partnership brings together two companies committed to driving improved patient care through meaningful technical innovation.

"Our goal is to help healthcare providers offer the best treatment option for their patients. The Premier agreement is important because it enables us to partner with a large sales force that has long-standing relationships with hospital-based clinicians and administrators to significantly increase visibility of the CyberKnife and TomoTherapy systems," said Kelly Londy, executive vice president and chief commercial officer of Accuray.

Premier has one of the nation's largest group purchasing organizations (GPOs). Under the new contract, Accuray's precise, clinically proven tumor treatments became available starting Sept. 1 to Premier member hospitals and providers. Premier unites an collective of more than 3,000 hospitals and 110,000 other providers, including oncology centers. In addition, the contract provides Accuray with access to key Premier integrated delivery network partners, where Accuray has had limited historical business presence.

"We believe the Premier agreement will provide improved deal visibility to radiation equipment purchasing decisions earlier in the process and, ultimately, result in new opportunities for Accuray equipment and services," said Joshua H. Levine, president and CEO of Accuray. "The partnership also validates our focus on service excellence and technology performance, and demonstrates the confidence the radiation oncology community has in the unique benefits of the CyberKnife and TomoTherapy Systems."

For more information: www.accuray.com


Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Radiology Business

July 3, 2024 — The American Society of Radiologic Technologists has launched the BeRAD Professionalism Award to ...

Time July 03, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | Radiation Oncology

June 3, 2024 — The American Society for Radiation Oncology (ASTRO) published an updated clinical guideline that details ...

Time June 03, 2024
arrow
News | Oncology Information Management Systems (OIMS)

May 30, 2024 — RaySearch Laboratories AB announced the release of the latest version of RayCare, the next generation ...

Time May 30, 2024
arrow
Subscribe Now